Taysha Gene Therapies, Inc. (TSHA) Total liabilities 2022–2025
Taysha Gene Therapies, Inc. (TSHA) total liabilities at each fiscal year-end, per SEC filings.
$96.4MFY2025 · since FY2022: $125.3M → $96.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $96.4M | +8.5% |
| FY2024 | $88.8M | -9.2% |
| FY2023 | $97.8M | -22.0% |
| FY2022 | $125.3M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More TSHA financial trends
TSHA RevenueTSHA Net incomeTSHA Net marginTSHA Gross profitTSHA Gross marginTSHA Operating incomeTSHA Operating marginTSHA Operating cash flowTSHA Free cash flowTSHA Capital expendituresTSHA Return on equityTSHA Stock buybacksTSHA Dividends paidTSHA Total assetsTSHA Shareholders’ equityTSHA overview →